BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies, Inc. (OTC: BSEM), a prominent MedTech company known for its innovative placental-derived products aimed at advanced wound care, is set to participate in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami. The event, scheduled for June 12-14, 2025, will feature the Company’s CEO, Jason Matuszewski, who will engage in a fireside chat and hold one-on-one meetings with conference attendees. For those interested in scheduling a meeting, Noah Agron, VP of Corporate Finance and Strategy, is available for contact.

BioStem is recognized for its pioneering development, manufacturing, and commercialization of allografts created from perinatal tissue. Their proprietary BioREtain® processing method is at the core of their offerings, ensuring the preservation of critical growth factors and the structural integrity of the tissue. This technique reflects the latest advancements in wound care, allowing BioStem to produce high-quality products that aim to improve patient outcomes.

The Company operates under stringent quality management systems accredited by the American Association of Tissue Banks (AATB), adhering to current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP). BioStem's product portfolio includes well-regarded brands such as AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®, which are all processed at their FDA-registered facility in Pompano Beach, Florida.

For updates on BioStem’s initiatives and advancements, interested parties can join the company’s distribution list and follow them on social media platforms like X and LinkedIn. More information can be accessed through their website or by contacting their investor relations team directly.

BioStem Technologies, Inc. (OTC: BSEM) is poised to enhance its visibility and market positioning by participating in the prestigious Goldman Sachs 46th Annual Global Healthcare Conference. As a leading MedTech company specializing in placental-derived products for advanced wound care, BioStem presents a compelling opportunity for investors focusing on innovation in the healthcare sector.

With Jason Matuszewski, CEO, leading the discussion in a fireside chat, investors should be keenly attuned to updates regarding the company's strategic direction and product pipeline. Given BioStem’s proprietary BioREtain® processing method, which preserves growth factors while maintaining tissue integrity, there’s strong potential for product differentiation in a competitive market. The company's diverse portfolio, which includes well-recognized brands such as AmnioWrap2™, enhances its market appeal.

From a financial perspective, investors should consider BioStem’s accreditation by the American Association of Tissue Banks (AATB) and adherence to regulatory standards like cGTP and cGMP, which underscores the company's commitment to quality and compliance. Such certifications not only elevate BioStem's credibility but also position it favorably against competitors.

Participation in the conference may lead to increased investor interest and potential partnerships, fostering growth opportunities. For those looking to engage personally, BioStem is encouraging one-on-one meetings, which could offer insights into growth strategies and operational details not publicly available.

Market conditions are volatility-laden, so it’s imperative to mitigate risk through thorough due diligence. BioStem has shown promising innovation in the wound care sector, which is increasingly relevant as the demand for effective treatment solutions rises. Investors should monitor BioStem Technologies closely in the lead-up to and following the conference for potential strategic announcements and market movements.